NCT01330966 - Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

February 28, 2018

Study Completion Date

February 28, 2018

Conditions

ChondrosarcomaMetastatic Chondrosarcoma

Interventions

DRUG

pazopanib

Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.

Trial Locations (7)

Pennsylvania Oncology Hematology Associates, Philadelphia

University of Iowa, Iowa City

Mayo Clinic, Rochester

Edward Cancer Center, Naperville

MD Anderson, Houston

City of Hope, Duarte

University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Queen Elizabeth Medical Centre, Edgbaston